Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Intravenous Fenretinide (4-HPR) Plus Intravenous Safingol for Patients With Relapsed Malignancies

NCT01553071 is registered in ClinicalTrials.gov with South Plains Oncology Consortium as lead sponsor.

NCT NCT01553071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01553071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Intravenous Fenretinide (4-HPR) Plus Intravenous Safingol for Patients With Relapsed Malignancies
Lead sponsor
South Plains Oncology Consortium
Phase
Phase 1
Overall status
Terminated
Start date
November 30, 2016
Completion date
December 31, 2020
Enrollment
16 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor